Clinical Trials on Rabies Human in New Zealand

Total 1264 results

The Methodist Hospital Research Institute
Grifols Biologicals, LLC

Completed

Improving Adherence to Rabies PEP Guideline Recommendations

Rabies | Rabies Human | Rabies Virus Infection

United States
Arrow Therapeutics

Completed

Antiviral Activity of AZD7295 in HCV Carriers

Hepatitis C

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Gilead Sciences

Completed

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

HCV Infection

New Zealand
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Hepatitis C Virus Infection

New Zealand
Enanta Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Hepatitis C

New Zealand
Assembly Biosciences

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults

Chronic Hepatitis B

New Zealand
Janssen Research & Development, LLC

Terminated

A Single and Multiple Ascending Dose Study of JNJ-64457744

Healthy | Hepatitis B, Chronic

New Zealand
Novartis Pharmaceuticals

Terminated

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Hepatitis C

New Zealand
Hoffmann-La Roche

Completed

A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic, Healthy Volunteer

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Chronic Hepatitis b

New Zealand
Assembly Biosciences

Completed

A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects

Chronic Hepatitis B

New Zealand
Antipodean Pharmaceuticals, Inc.

Completed

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Chronic Hepatitis C

New Zealand
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
Arrowhead Pharmaceuticals

Terminated

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Hepatitis B

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Assembly Biosciences

Completed

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

New Zealand
Enanta Pharmaceuticals, Inc

Terminated

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Chronic Hepatitis B Virus Infection

New Zealand
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Chronic Hepatitis B

New Zealand
Gilead Sciences

Completed

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Chronic Hepatitis C Infection

New Zealand
Virion Therapeutics

Recruiting

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Chronic Hepatitis B

Hong Kong, New Zealand
Novira Therapeutics, Inc.

Completed

Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Chronic Hepatitis B

New Zealand
Aligos Therapeutics

Terminated

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Chronic Hepatitis B

United Kingdom, New Zealand
Arrow Therapeutics
DDS, Dundee; David Mutimer, Birmingham; Ed Gane, ACS New Zealand

Terminated

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers (CP104)

Chronic Hepatitis C

New Zealand, United Kingdom
Soroka University Medical Center
Eiger BioPharmaceuticals

Active, not recruiting

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection (LOWR6)

Hepatitis D, Chronic

Israel, New Zealand, Turkey
Novartis
Novartis Pharmaceuticals

Completed

Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

Hepatitis B

Hong Kong, Singapore, New Zealand
Gilead Sciences

Completed

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Chronic Hepatitis B

United States, New Zealand
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Hoffmann-La Roche

Completed

A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Hepatitis C, Chronic

New Zealand, Australia
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Hepatitis B, Chronic

New Zealand
Eiger BioPharmaceuticals

Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Hepatitis D, Chronic

Israel, New Zealand, Pakistan
Hoffmann-La Roche

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients

Hepatitis B, Chronic

Hong Kong, Taiwan, New Zealand
Arbutus Biopharma Corporation

Completed

Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

Hepatitis B, Chronic

Australia, New Zealand
Gilead Sciences

Completed

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

HCV Infection

United States, Germany, New Zealand
Macfarlane Burnet Institute for Medical Research...
St Vincent's Hospital Melbourne

Completed

The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital

Hepatitis C

Australia, New Zealand
Syneos Health
F-star Therapeutics, Inc.

Completed

A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

Hepatitis C Infection

Australia, New Zealand
Kirby Institute

Completed

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)

Hepatitis C

Australia, New Zealand
Gilead Sciences

Completed

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

HCV Infection

United States, New Zealand, Germany
Janssen Research & Development, LLC

Terminated

A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Hepatitis C

Singapore, Canada, Poland, New Zealand
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Hepatitis B Virus

United States, Germany, New Zealand
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Terminated

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Australia, New Zealand
Aligos Therapeutics

Terminated

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Chronic Hepatitis B

New Zealand, Bulgaria, Moldova, Republic of, Romania
Arrowhead Pharmaceuticals

Completed

Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

Hepatitis B

Australia, Hong Kong, New Zealand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Australia, New Zealand
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Hepatitis C Virus

United States, New Zealand

3

Subscribe